Key result
Treatment with bortezomib combined with cisplatin and gemcitabine induced severe but reversible congestive cardiac failure in a 53-year-old lung cancer patient with subclinical baseline cardiomyopathy.
Case Report (n=1)
Bortezomib treatment may induce severe but reversible congestive cardiac failure, highlighting the need for careful cardiac monitoring in patients with pre-existing subclinical left ventricular dysfunction.
Answers are grounded in this paper and cite their sources.
May support cardiac monitoring in subclinical cardiomyopathy on bortezomib regimens; hypothesis-generating and requires prospective confirmation.
BACKGROUND: Bortezomib (Velcade), a dipeptide boronate proteasome inhibitor, is a novel anti-cancer agent registered for multiple myeloma (MM). It has also shown promising clinical activity in non-small cell lung cancer (NSCLC). Clinical experience with bortezomib so far indicates that overall incidence of cardiac failure associated with bortezomib therapy remains incidental. Nevertheless, acute development or exacerbation of congestive cardiac failure has been associated with bortezomib treatment. CASE PRESENTATION: We present here a case of severe, but reversible, congestive cardiac failure in a lung cancer patient who had no prior cardiac history, after receiving an experimental treatment of bortezomib combined with chemotherapy. Elevated levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), as retrospectively measured in archived serum samples, were suggestive of pre-existent (sub-clinical) left ventricular dysfunction. CONCLUSION: Based on literature, we hypothesize that baseline presence of sub clinical cardiomyopathy, characterized by a dysregulation of the ubiquitin-proteasome system, could have predisposed this patient for a cardiac side effect induced by systemic proteasome inhibition. Patients with heart disease or risk factors for it should be closely monitored when being submitted to treatment with proteasome inhibition therapy such as bortezomib. Caution is therefore warranted in lung cancer patients who often present with cardiac comorbidities.
No takes yet. Share an insight, caveat, or question.
Voortman et al. (2006) conducted a case report in Non-small cell lung cancer (n=1). Bortezomib combined with cisplatin and gemcitabine was evaluated on Development of congestive cardiac failure. Treatment with bortezomib combined with cisplatin and gemcitabine induced severe but reversible congestive cardiac failure in a 53-year-old lung cancer patient with subclinical baseline cardiomyopathy.
Synapse has enriched 10 related papers. Consider them for comparative context: